NEW YORK, NY, July 20, 2020 (GLOBE NEWSWIRE) — Halfway through 2020 and World High Life (OTCQB: WRHLF) has seen considerable sales numbers lead to two substantial quarters of growth from its wholly owned subsidiary, Love Hemp. Tony Calamita, the Chief Executive Officer (CEO) of Love Hemp, a London-based CBD company spearheading the development of the United Kingdom’s (UK) leading range of trusted CBD products, has the company hitting on all cylinders as it heads into the second half of the year. Although the global COVID-19 crisis has many businesses treading water and searching for answers, Love Hemp hasn’t missed a beat while meeting these trying times head on, the company has thrived by giving customers exactly what they want—plenty of online options and continued product development.Love Hemp has over 80 products, including oils, sprays, edibles, cosmetics, and vapes, and the company currently enjoys around 1,200 retail listings, but World High Life’s subsidiary has no plans of stopping there. Love Hemp prides itself on understanding market demand and developing new products and brands that satisfy what consumers want most. Calamita says that new product development is at the heart of everything the company does. “We currently have 15 new products in the development stage, and we remain committed to creating the UK’s leading range of trusted CBD products.”Last week, one of those newly developed brands was launched into the market. World High Life announced Love Hemp’s new brand, Buzz Leaf, a host of products aimed at younger consumers that include the release of four broad-spectrum CBD infused e-liquids with added terpenes, and eventually the launch of a full range of CBD products, including CBD oils and capsules. According to the company, the e-liquids feature exotic flavors that contain 500mg of CBD.Given the exponential growth that the company’s e-commerce business has seen and the sheer number of customers, who are not only finding Love Hemp online but continuing to come back again and again, Love Hemp has redesigned its global online retailer, https://www.CBDOilsUK.com, a premium CBD oil and cannabidiol supplier in the UK, to handle the overwhelming demand. Calamita says that with the launch of the Buzz Leaf products, there is now something for everyone on the website.Tony Calamita, discussing the successful results that Love Hemp has enjoyed in Q1 and Q2 said, “The COVID-19 pandemic affected consumer markets and is accelerating existing trends within the consumer sector. When the pandemic began, we saw a shift in retail, which resulted in the acceleration of the e-commerce market as consumer demand shifted to shopping online.“As a result, we achieved a 107% increase in online sales from January to May 2020. This was an incredibly strong period of sales for Love Hemp, and while our strong growth usually comes from a wider variety of sales channels, given the challenging business circumstances, our shift to the expansion of our online products has enabled us to ensure our customers are able to continue to purchase and to engage with us. We are focused on building trust and credibility with our consumer base and to continue to innovate while responding to evolving consumer demands.”Sales of the company’s CBD oil, CBD oil sprays, and CBD soft gel capsules are leading the way, but the timely introduction of another new product, Love Hemp Immune, well ahead of schedule, is already growing in popularity among customers. Love Hemp Immune is advertised as a blend of CBD, essential vitamins, including vitamins C and D, and bilberry extract to maintain a healthy immune system by supporting our body’s natural defenses.Calamita added, “We’ve also seen a greater interest in health and wellness as COVID-19 reinforced the importance of being healthy and maintaining a strong, balanced immune system.“Since its launch, Love Hemp Immune has been well received by consumers. It was a product that was due to launch in the Winter of 2020, but, instead, we worked around the clock to ensure that consumers could have access to it much sooner as COVID-19 and a nationwide lockdown hit the UK, a time when boosting our immune systems has rarely felt more urgent. It contains the perfect combination of beneficial ingredients to help boost the body’s natural defenses. The importance of being flexible and agile while responding to consumer needs has never been more crucial.”So, where does World High Life’s subsidiary go in the second half of the year? The announcement of the Buzz Leaf brand is certainly a good start and defines what is likely Love Hemp’s plan to get those 15 products/brands that are in development to market. Love Hemp’s CEO says, “As retail stores begin to reopen, we’re focused on holistic growth across all channels from retail to online. We are in conversations with all major retailers in the UK, and we look forward to continued growth among our customer base, while maintaining brand loyalty among consumers.”To learn more about World High Life visit: https://www.worldhighlife.ukTo learn more about Love Hemp visit: https://www.love-hemp.comTo learn more about the new Buzz Leaf product line visit: https://www.cbdoilsuk.comFor direct questions, call their toll-free number in North America: 1-888-616-9745About World High LifeWorld High Life PLC is an investment company with a strategic focus to invest in and/or acquire companies operating in the CBD wellness and medicinal cannabis industry. The Company’s wholly owned subsidiary, Love Hemp Ltd., is one of the UK’s leading CBD and Hemp product suppliers and has more than 40 product lines, comprising oils, sprays and vapes, and a variety of edible and water-based CBD products. Love Hemp has established relationships with over 1,200 stores in the UK, including leading brands such as Ocado, Holland & Barrett, and WH Smith.About Stock Market Media GroupStock Market Media Group is a news & media content development IR firm offering a platform for corporate stories to unfold in the media with press releases, research reports, corporate videos, radio-style CEO interviews, and feature news articles.This article was written based on publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets, and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at www.sec.gov, where you can also find all of World High Life’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks. We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell, or offer to buy any security. Our publications about World High Life are not a recommendation to buy or sell a security.Should Stock Market Media Group and its management own shares in the profiled company, they may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company’s profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it was remunerated one-thousand, two hundred dollars paid for by a third party (to date: four-thousand, eight hundred dollars total) via bank wire, to produce content related to World High Life.Stock Market Media Group and its management do not own any shares in World High Life and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company’s stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company’s profile, our disclaimer will be updated accordingly to reflect the current position of any free trading shares received as compensation for our services.For more information: www.stockmarketmediagroup.com.Contact:Stock Market Media Group firstname.lastname@example.org
Successful completion of feasibility study for the development of topical medical cannabis products based on AKVANO® technology
Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for the development of IP protected, homogeneous, topical medical Cannabis products for the treatment of skin inflammation, including psoriatic lesions.
Product development of such topical medical Cannabis products based on AKVANO® is being conducted under a collaboration between Cannassure and Lipidor AB (“Lipidor”), a Swedish topical drug development company, owner of the proprietary drug delivery platform technology AKVANO™, which was signed in December 2019. The development project budget is partially funded by the Israeli Innovation Authority, by a non-dilutive grant.
The product under development is an incorporation of cannabinoids with AKVANO®, a topical drug delivery platform. Successful development of the product will allow localized administration of a precise dosage of cannabinoids using a spray, in a technology that allows for prolonged contact and optimal penetration of the active ingredient into the skin.
As part of the feasibility study, AKVANO® technology and cannabinoids were tested for compatibility, and it was found that the cannabinoids can be successfully combined in the AKVANO® system for a homogeneous, uniform and stable formulation. Cannassure tested the degree of product penetration into the skin by using known and acceptable models and found significant penetration of active ingredients into the skin tissue. This enhanced penetration may increase the therapeutic potential of the product. Based on these results, Cannassure will proceed to accelerated development stages and more advanced testings.
According to the agreement, Cannassure has informed Lipidor on its intention to start negotiating an exclusive global license for the use of Lipidor’s technology for the development of cannabinoids based topical therapeutics products for the treatment of indications to be chosen by Cannassure.
The main guidelines for the licencing agreement, including royalties to be paid to Lipidor on product sales, were defined in the collaboration agreement.
According to estimates, the global market for products for the treatment of psoriasis is expected to reach 21.1 billion dollars by 20221. The current global market for topical products for the treatment of psoriasis is valued at 7 billion dollars2, and the global market for topical pain treatment products is projected to reach 13 billion dollars3.
The product development of topical treatments based on cannabinoids is in line with Cannassure’s strategy focused on the development and commercialisation of innovative medical cannabis products based on established drug delivery systems and formulations for enhanced therapeutic value. The product development is performed under the Israeli Medical Cannabis regulation, which allows a short development process.
Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company’s AKVANO® technology
Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. , an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the joint development agreement signed in December 2019, Cannassure has now announced that it intends to exercise its option and begin the negotiation of an exclusive licensing agreement for the use of AKVANO®, Lipidor’s proprietary drug delivery technology, for the indications chosen by Cannassure. The main guidelines for the licencing agreement, including royalties (double digit) to be paid to Lipidor on product sales, were defined in the collaboration agreement.
The collaboration began with an evaluation of the possibility of incorporating various active drug substances from the cannabis plant into AKVANO®. The formulation work has been carried out in Israel at Cannassure’s state-of-the-art facilities with support from Lipidor’s formulation experts.
The product under development is based on a topical medical cannabinoid that has been incorporated into the AKVANO® formulation platform. The successful development of the product will make it possible to administer the medical cannabinoid as a spray, locally and in the exact desired amount, which together ensures improved contact and optimal penetration of the active substance into the skin.
As part of the feasibility study, AKVANO® technology and cannabinoids were tested for compatibility, demonstrating that cannabinoids can be combined in the AKVANO® system as a homogeneous, uniform and stable formulation. Cannassure tested the degree of product penetration into the skin using known and accepted models and found significant penetration of active ingredients into skin tissue. This improved penetration may increase the therapeutic potential of the product. According to Cannassure, based on these results, the company will go ahead, accelerating the pace of development steps and conducting more advanced testing. Cannassure will implement the technology for the development and commercialization of sprayable medicinal cannabis products based on AKVANO®.
The common goal is to introduce innovative topical treatments to the fast-growing global market for medical cannabis products.
“We are very pleased with the positive outcome of the feasibility study, which confirms our previous high hopes. The result is an important milestone for Lipidor and for our unique formulation platform, showing that cannabinoids can be incorporated into AKVANO®. The collaboration with our partner Cannassure represents significant commercial potential for Lipidor,” says Ola Holmlund, CEO of Lipidor AB.
“We look forward to continued successful cooperation with Cannassure in the field of medical cannabis.”
This disclosure contains information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-09-2020 08:00 CET.
Christina Lake Announces Commencement of Trading on the CSE
VANCOUVER, British Columbia, Sept. 29, 2020 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”), a premier producer of high-quality, low-cost, sun-grown cannabis flower, oil cannabinoids, as well as hemp-based extracts and derivatives, serving domestic and international markets, is pleased to announce that its common shares will begin trading on the Canadian Securities Exchange (“CSE”) at 9:30 am EDT on Thursday October 1, 2020 under the ticker symbol “CLC”.
In October 2018, CLC began its roadmap to becoming one of the largest firms in the country for outdoor cannabis cultivation and extraction by purchasing a cultivation building and fully-serviced 32-acre site in the Christina Lake region of British Columbia. CLC received approval for a standard cultivation license from Health Canada in early 2019, with a research and development license granted in the beginning of 2020. In summer 2020 the Company began harvesting more than 22,500 plants of eight unique cannabis strains, which is expected to yield a minimum of 22,500 kg/49,500 lb. With over 30 full-time staff members and seasonal workers, CLC is also the largest employer in its region. To date, the Company’s successive investment rounds have raised a total of approximately CAD $16,000,000, which enables CLC to maintain a reserve of funds for ongoing operations.
Nicco Dehaan, a founder of the Company and its Chief Operating Officer commented, “Having been part of CLC from the beginning, I am very proud of the progress made since 2018 for both the Company and the cannabis industry in general. We were very confident in the amount of growth potential this industry had, and we knew Christina Lake would be the perfect region in which to conduct outdoor growing of cannabis. As with any regulated industry, there were many hoops to jump through in order to obtain license approvals and build out a compliant operating structure. Further, applying to have CLC’s equity traded on a public stock exchange introduces a whole other set of requirements to meet and satisfy on an ongoing basis. Between obtaining our licensed producer status from Health Canada, hiring on full-time personnel for several key professional roles, and beginning to harvest our first crop for the 2020 growing season, receiving approval for trading on the CSE is an excellent addition to our momentum as we prepare to bring our first crop to market. We look forward to a productive Q4 2020, with very exciting developments to be had in 2021 and beyond.”
About Christina Lake Cannabis Corp.
Christina Lake Cannabis Corp is a Licensed Producer of cannabis under the Cannabis Act which also received a Research and Development License from Health Canada on May 20, 2020. CLC’s facility is comprised of a 32-acre property, which includes over 950,000 square feet of outdoor grow space, offices, propagation and drying rooms, as well as research facilities, and a facility dedicated to processing and extraction. CLC cultivates cannabis using strains specifically developed for outdoor cultivation and expects to produce 22,500 kg or more from its 32-acre facility before developing its adjacent 99-acre expansion property, which will bring its cultivation footprint to over 4.35 million square feet or over 88,000 kg of low-cost, high-quality, sun-grown cannabis annually.
For more information about CLC, please visit: www.clcannabis.com
On behalf of Christina Lake Cannabis Corp.:
Joel Dumaresq, CEO and Director
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.
Cannabis4 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis3 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis4 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis3 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis2 weeks ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)
Cannabis4 weeks ago
Fernhill Beverage Branches Out for Success!
Cannabis4 weeks ago
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru
Cannabis3 weeks ago
Monument Health Chooses Nuance Dragon Ambient eXperience to Transform Physician-Patient Encounters with Ambient Clinical Intelligence